bictegravir

Although the action was light on the FDA approval front, biotech stocks took the spotlight in January, thanks to a few multi-billion-dollar deals announced in the space. Celgene Corporation (NASDAQ: CELG) announced a deal to buy Juno Therapeutics Inc (NASDAQ: JUNO). Ahead of that deal,...

The Street may be too optimistic in its outlook for Gilead Sciences, Inc. (NASDAQ: GILD) — and this isn't a bullish indicator, according to Credit Suisse. The Analyst Credit Suisse's Alethia Young downgraded Gilead's stock rating from Outperform to Neutral with a price target...

BMO Capital Markets' M. Ian Somaiya maintained a Market Perform rating on Gilead Sciences, Inc. (NASDAQ: GILD) with a price target boosted from $75 to $76 after the company reported its first quarter results. Gilead's reported revenues of $6.5 billion fell short of the $6.66 billion...